CareDx acquires Naveris for $160 million with potential $100 million milestone payments
Updated
Updated · MarketWatch · Apr 28
CareDx acquires Naveris for $160 million with potential $100 million milestone payments
2 articles · Updated · MarketWatch · Apr 28
The acquisition includes an upfront $160 million cash payment and up to $100 million in revenue-based milestones, with closing expected in the third quarter of 2026.
Naveris, which reported $34 million in 2025 revenue and employs about 100 people, specializes in precision oncology diagnostics for HPV-driven cancers and has performed over 130,000 commercial tests.
CareDx, based in Brisbane, California, focuses on healthcare solutions for transplant patients; its shares fell 7% after the announcement, despite a slight gain during regular trading.
Why did investors react negatively to CareDx's $260 million oncology bet?
What does this deal signal for the future of cancer diagnostic startups?
How will Naveris's viral DNA test change HPV-cancer patient monitoring?
How will new Medicare coverage laws impact this acquisition's profitability?
Can advanced diagnostics justify their high cost in modern cancer care?